CN103555763B - IL-2 and MART-1 double gene coexpression recombinant vectors and its preparation method and application - Google Patents
IL-2 and MART-1 double gene coexpression recombinant vectors and its preparation method and application Download PDFInfo
- Publication number
- CN103555763B CN103555763B CN201310571900.7A CN201310571900A CN103555763B CN 103555763 B CN103555763 B CN 103555763B CN 201310571900 A CN201310571900 A CN 201310571900A CN 103555763 B CN103555763 B CN 103555763B
- Authority
- CN
- China
- Prior art keywords
- mart
- primer
- gene
- pires2
- recombinant vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of IL-2 and MART-1 double gene coexpression recombinant vectors, it is connected with IL-2 gene, IRES sequence and MART-1 gene in turn along carrier transcriptional orientation, or is connected with MART-1 gene, IRES sequence and IL-2 gene in turn along carrier transcriptional orientation; Is the nucleotide sequence of described IL-2 gene as SEQ in sequence table? ID? is the nucleotide sequence of described MART-1 gene as SEQ in sequence table shown in NO:1? ID? is the nucleotide sequence of described IRES sequence as SEQ in sequence table shown in NO:2? ID? shown in NO:3.Double gene coexpression recombinant vectors of the present invention, IRES sequence is adopted to connect IL-2 gene and MART-1 gene, Humanmachine tumour differentiation antigen and Human Inter Leukin-2 can be expressed in identical carrier simultaneously, this recombinant vectors can be used for melanomatous Gene immunotherapy, the immunoregulation effect of cytokine can be played, specificity antineoplastic effect can be produced for melanoma in targeting ground again.
Description
Technical field
The present invention relates to a kind of recombinant vectors and its preparation method and application, particularly relate to a kind of double gene coexpression recombinant vectors and its preparation method and application.
Background technology
Melanoma (Melanoma), also known as malignant melanoma (Malignant Melanoma, MM), it is the malignant tumour deriving from neural crest melanocyte, multiplely be born in skin volume table, also be found in choroid, pia mater and digestive tube etc., its grade malignancy is high, is the malignant tumour that in superficial tumor, mortality ratio is the highest.In recent years, melanomatous sickness rate and corresponding mortality ratio are increasing rapidly, and age of onset more and more early, and the health of the mankind in serious threat.
Melanomatous traditional treatment is the complex therapy comprising operation, chemotherapy, immunotherapy etc.At present unique effective methods for the treatment of is when tumor thickness is less than 1 millimeter by ocal resection, but due to melanomatous height Invasion and Metastasis and the resistance to Treated with Chemotherapeutic Drugs thing, causes its unsatisfactory curative effect and prognosis mala.For the situation of tumour patient ubiquity hypoimmunity, the specificity antineoplastic immunity of body is induced to react, with the growth of Tumor suppression, transfer and recurrence by immunotherapy.In recent years, the vaccine carrying external source specific tumor antigen has become the new direction of immunotherapy of tumors, comprises gene vaccine, tumour-cell vaccine, bacterial vaccine, virus vaccines and dendritic cell vaccine etc.Wherein, gene vaccine is by the methods for the treatment of of specific support by medicative for tool gene into cells; But gene therapy can only improve certain gene pairs the short period of time and answer protein expression level, and its curative effect lasting time is short, lacks long-term anti-tumor capacity.
Why tumour can breed in vivo, shift, and is can the molecule of activated T cell because lack MHC antigen etc., thus can not by T cell identification, cannot the active immunity of activated T cell mediation.Therefore, the anti-tumor immune response of inducing potent, not only need the expression of tumor associated antigen and present, also need to strengthen costimulatory molecules and cytokine mediated immunization.
Human Inter Leukin-2 (Interleukin-2, IL-2), has another name called SCIF (T Cell Growth Factor, TCRF).IL-2 is under mitogenesis element or specific antigens stimulate, a kind of cytokine in organism immune response with important regulative produced by T lymphocyte or T lymphocyte series.IL-2 is the core substance in Organism immunoregulation network, has collaborative and antagonistic action, jointly complete the Balanceregulation of human body immune function with other cytokines; It can stimulate activation and the propagation of NK, CTL, LAK cell, also can impel T lymphocyte, NK Cells Interferon Production, tumour necrosis factor etc., thus can be widely used in the treatment of antiviral, bacterial-infection resisting and the disease such as antitumor.In the pathogenesis of malignant tumour, due to immunologic hypofunction, the killer cell hypofunctions such as NK, CTL, LAK in neoplastic disease human body, normally can not remove tumour cell, and the activation of these killer cell and propagation are all based on IL-2, now must provide external source IL-2, help patient to complete immune surveillance function, the amynologic basis of IL-2 treatment tumour that Here it is.IL-2 is used alone or is used from the treatment of metastasis melanin tumor with Tumor-infiltrating lymphocytes and tumor infiltrating lymphocyte one, achieves good clinical effectiveness.But current IL-2 Gene immunotherapy method just improves the IL-2 protein expression level of body partly, and its immunoregulation effect, anti-tumor capacity are less, and lack the targeting of immunotherapy.
MART-1(Humanmachine tumour differentiation antigen) be the related antigen of Melanoma Differentiation, it is ripe that it participates in melanosome, be expressed in melanoma and melanoma cell series, express in most steroid tumour (comprising adrenal cortical tumor), melanocytic lesion and hemanyiopericytoma.MART-1 has stronger immunogenicity, is easy to be identified by cytotoxic T lymphocyte (CTL), produces effective antitumour immunne response, is considered to the best candidate of melanoma immunotherapy.
Summary of the invention
Based on this, be necessary the defect existed for prior art, a kind of IL-2 and MART-1 double gene coexpression recombinant vectors is provided, this recombinant vectors can be used for melanomatous Gene immunotherapy, the immunoregulation effect of cytokine can be played, specificity antineoplastic effect can be produced for melanoma in targeting ground again.
Another object of the present invention is, provides the preparation method of described IL-2 and MART-1 double gene coexpression recombinant vectors.
Another object of the present invention is, provides the application of described IL-2 and MART-1 double gene coexpression recombinant vectors in melanoma immunotherapy.
IL-2 and MART-1 double gene coexpression recombinant vectors, it is connected with IL-2 gene, IRES sequence and MART-1 gene in turn along carrier transcriptional orientation, or is connected with MART-1 gene, IRES sequence and IL-2 gene in turn along carrier transcriptional orientation; The nucleotide sequence of described IL-2 gene is as shown in SEQ ID NO:1 in sequence table, and the nucleotide sequence of described MART-1 gene is as shown in SEQ ID NO:2 in sequence table, and the nucleotide sequence of described IRES sequence is as shown in SEQ ID NO:3 in sequence table.
Wherein in an embodiment, described carrier is pIRES2-EGFP plasmid vector, and described double gene coexpression recombinant vectors is pIRES2-IL-2-MART-1 recombinant vectors; Wherein, IL-2 gene is positioned at the upstream of IRES sequence, and MART-1 gene is positioned at the downstream of IRES sequence.
Wherein in an embodiment, described carrier is pIRES2-EGFP plasmid vector, and described double gene coexpression recombinant vectors is pIRES2-MART-1-IL-2 recombinant vectors; Wherein, MART-1 gene is positioned at the upstream of IRES sequence, and IL-2 gene is positioned at the downstream of IRES sequence.
The preparation method of IL-2 and MART-1 double gene coexpression recombinant vectors of the present invention, comprises the following steps:
1) the IL-2 gene fragment containing specific cleavage site or MART-1 gene fragment is obtained;
2) IL-2 gene fragment step 1) obtained or MART-1 gene fragment are connected to carrier, build the recombinant vectors containing IL-2 gene or MART-1 gene;
3) MART-1 gene fragment or the IL-2 gene fragment of cutting sticky end containing enzyme is obtained;
4) MART-1 gene fragment step 3) obtained or IL-2 gene fragment are connected to step 2) recombinant vectors that obtains, IL-2 and the MART-1 double gene coexpression recombinant vectors described in structure.
Wherein in an embodiment, the preparation method of described pIRES2-IL-2-MART-1 recombinant vectors, comprises the following steps:
A) the IL-2 gene fragment containing specific cleavage site is obtained: obtain cDNA as template from CIK cell, pcr amplification is carried out with the IL-2 Auele Specific Primer containing EcoR I and BamH I restriction enzyme site sequence, obtain the IL-2 gene fragment containing EcoR I and BamHI restriction enzyme site, its nucleotide sequence is as shown in SEQ ID NO:6 in sequence table;
B) build pIRES2-IL-2-EGFP recombinant vectors: with restriction enzyme EcoR I, BamH I respectively enzyme cut pIRES2-EGFP plasmid and steps A) the IL-2 gene fragment that obtains, and adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-IL-2-EGFP recombinant vectors;
C) the MART-1 gene fragment of cutting sticky end containing enzyme is obtained: obtain cDNA as template from melanoma cell A375, pcr amplification is carried out with the MART-1 Auele Specific Primer cutting sticky end containing BstX I and Not I enzyme, the PCR reaction product obtained is carried out hybridization PCR again and is reacted, obtain MART-1 gene fragment mixture, a kind of MART-1 gene fragment wherein has BstX I and Not I enzyme cuts sticky end;
D) pIRES2-IL-2-MART-1 recombinant vectors is built: cut step B with restriction enzyme BstX I, Not I enzyme) the pIRES2-IL-2-EGFP recombinant vectors that obtains, by step C) the MART-1 gene fragment mixture and the enzyme that obtain cut rear linearizing pIRES2-IL-2-EGFP recombinant vectors and mix, adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-IL-2-MART-1 recombinant vectors.
Wherein in an embodiment, steps A) described in IL-2 Auele Specific Primer be:
IL-2 upstream primer: 5 '-CCGGAATTCATGTACAGGATGCAACTCC-3 ',
IL-2 downstream primer: 5 '-CGCGGATCCTCAAGTCAGTGTTGAGATGATGC-3 '.
Wherein in an embodiment, step C) described in MART-1 Auele Specific Primer comprise MART-1 first primer pair and MART-1 second primer pair, described MART-1 first primer pair is made up of MART-1 upstream long primer and MART-1 downstream long primer, and described MART-1 second primer pair is made up of MART-1 upstream short primer and MART-1 downstream short primer:
MART-1 first primer pair is:
MART-1 upstream long primer: 5'-AACCATGCCAAGAGAAGATGCTCACT-3',
MART-1 downstream long primer: 5'-GGCCGCTTAAGGTGAATAAGGTG-3';
MART-1 second primer pair is:
MART-1 upstream short primer: 5'-ATGCCAAGAGAAGATGCTCACTTCATC-3',
MART-1 downstream short primer: 5'-GCTTAAGGTGAATAAGGTGGTGGTGAC-3'.
Wherein in an embodiment, the preparation method of described pIRES2-MART-1-IL-2 recombinant vectors, comprises the following steps:
A) the MART-1 gene fragment containing specific cleavage site is obtained: obtain cDNA as template from melanoma cell A375, pcr amplification is carried out with the MART-1 Auele Specific Primer containing Xho I and EcoR I restriction enzyme site sequence, obtain the MART-1 gene fragment containing Xho I and EcoR I restriction enzyme site, its nucleotide sequence is as shown in SEQ ID NO:13 in sequence table;
B) build pIRES2-MART-1-EGFP recombinant vectors: with restriction enzyme Xho I, EcoR II respectively enzyme cut the MART-1 gene fragment that pIRES2-EGFP plasmid and step a) obtain, and adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-MART-1-EGFP recombinant vectors;
C) the IL-2 gene fragment of cutting sticky end containing enzyme is obtained: obtain cDNA as template from CIK cell, pcr amplification is carried out with the IL-2 Auele Specific Primer cutting sticky end containing BstX I and Not I enzyme, the PCR reaction product obtained is carried out hybridization PCR again and is reacted, obtain IL-2 gene fragment mixture, a kind of IL-2 gene fragment wherein has BstX I and Not I enzyme cuts sticky end;
D) pIRES2-MART-1-IL-2 recombinant vectors is built: cut with restriction enzyme BstX I, Not I enzyme the pIRES2-MART-1-EGFP recombinant vectors that step b) obtains, the IL-2 gene fragment mixture and the enzyme that step c) are obtained are cut rear linearizing pIRES2-MART-1-EGFP recombinant vectors and are mixed, adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-MART-1-IL-2 recombinant vectors.
Wherein in an embodiment, the MART-1 Auele Specific Primer described in step a) is:
MART-1 upstream primer: 5 '-AACTCGAGATGCCAAGAGAAGATGC-3 ',
MART-1 downstream primer: 5 '-CGGAATTCTTAAGGTGAATAAGGTG-3 '.
Wherein in an embodiment, IL-2 Auele Specific Primer described in step c) comprises IL-2 first primer pair and IL-2 second primer pair, described IL-2 first primer pair is made up of IL-2 upstream long primer and IL-2 downstream long primer, and described IL-2 second primer pair is made up of IL-2 upstream short primer and IL-2 downstream short primer:
IL-2 first primer pair is:
IL-2 upstream long primer: 5'-AACCATGTACAGGATGCAACTCCTGTCTT-3',
IL-2 downstream long primer: 5'-GGCCGCTCAAGTCAGTGTTGAGATGAT-3';
IL-2 second primer pair is:
IL-2 upstream short primer: 5'-ATGTACAGGATGCAACTCCTGTCTT-3',
IL-2 downstream short primer: 5'-GCTCAAGTCAGTGTTGAGATGATGC-3'.
The application of IL-2 and MART-1 double gene coexpression recombinant vectors of the present invention in melanoma Gene immunotherapy.
Wherein in an embodiment, after the dendritic cell be separated described IL-2 with MART-1 double gene coexpression recombinant vectors transfection melanoma patients self or allosome in patients with implantation body, carry out melanoma Gene immunotherapy.
IL-2 and MART-1 double gene coexpression recombinant vectors of the present invention, IRES sequence is adopted to connect IL-2 gene and MART-1 gene, Humanmachine tumour differentiation antigen (MART-1) and Human Inter Leukin-2 (IL-2) can be expressed in identical carrier simultaneously, the consumption of genophore can be reduced, reduce the introducing of the exogenous gene sequence that non-treatment is correlated with.Wherein, MART-1 is the related antigen of tumor-targeting, IL-2 is the cytokine playing immunoregulation effect, both conbined usage, both can play cytokine immunoregulation effect, specific anti-tumour effect can be produced in targeting ground again, thus better melanoma immunotherapeutic effects can be obtained.After the dendritic cell that double gene coexpression recombinant vectors transfection melanoma patients self or allosome are separated in patients with implantation body, the great expression of MART-1, dendritic cell submission MART-1 polypeptide and MHC mixture can be stimulated, and then stimulation body immune system, produce specific killing T cell, targeting kills and wounds the tumour cell of expressing MART-1 polypeptide; And the great expression of IL-2, energy enhancing body immunoregulation capability further, and amplification ability and the cell viability of T lymphocyte specific can be strengthened, increasing highly active T cell produces Interferon, rabbit, collaborative expansion antineoplastic immune effect.
IRES sequence derives from some virus and one section of non-translational region holding of cell mRNA 5 ', the mode that can not rely on cap starts the mRNA translation of far-end, jointly can transcribe with the gene be attached thereto under the control of upstream promoter, same transcript translates different albumen.When IRES connection polygene carries out coexpression, the mRNA of multiple gene is on same transcripton, but the translation process after transcribing is separate, upstream gene is translated in a conventional manner, downstream gene relies on IRES sequence to translate in the mode not relying on cap, ensure that absolute construction and the function of each gene.Utilize IRES to replace internal promoter, polygene co-expression carrier not only can be made greatly to reduce, but also overcome the mutual suppression phenomenon in traditional polygene expression vector between promotor, avoid the generation of fusion rotein.
Accompanying drawing explanation
Fig. 1 is the electrophorogram of the IL-2 gene fragment containing specific cleavage site sequence of embodiment one gained, and wherein, 1 is IL-2 gene, and M is mark;
Fig. 2 is pIRES2-EGFP plasmid map;
Fig. 3 is the pIRES2-IL-2-EGFP recombinant vectors collection of illustrative plates of embodiment two gained;
Fig. 4 is that the PCR of the pIRES2-IL-2-EGFP recombinant vectors of embodiment two gained identifies electrophorogram, and wherein, 1 is PCR reaction product, and M is mark;
Fig. 5 is that the enzyme of the pIRES2-IL-2-EGFP recombinant vectors of embodiment two gained cuts qualification electrophorogram, and wherein, 1 is endonuclease reaction product, and M is mark;
Fig. 6 is the electrophorogram of the MART-1 gene fragment with restriction enzyme sticky end of embodiment three gained, and wherein, 1 is pcr amplification product A, and 2 is that pcr amplification product B, M are for marking;
The schema that Fig. 7 reacts for the hybridization PCR described in embodiment three;
Fig. 8 is the pIRES2-IL-2-MART-1 recombinant vectors collection of illustrative plates of embodiment four gained;
Fig. 9 is that the enzyme of the pIRES2-IL-2-MART-1 recombinant vectors of embodiment four gained cuts qualification electrophorogram, wherein, 1 is EcoR I/BamH I double digestion reaction product, and 2 is BamH I/Not I double digestion reaction product, 3 is EcoR I/Not I double digestion reaction product, and M is mark.
Figure 10 is the electrophorogram of the MART-1 gene fragment containing specific cleavage site sequence of embodiment five gained, and wherein, 1 is MART-1 gene, and M is mark;
Figure 11 is the pIRES2-MART-1-EGFP recombinant vectors collection of illustrative plates of embodiment six gained;
Figure 12 is that the PCR of the pIRES2-MART-1-EGFP recombinant vectors of embodiment six gained identifies electrophorogram, and wherein, 1 is PCR reaction product, and M is mark;
Figure 13 is that the enzyme of the pIRES2-MART-1-EGFP recombinant vectors of embodiment six gained cuts qualification electrophorogram, and wherein, 1 is endonuclease reaction product, and M is mark;
Figure 14 is the electrophorogram of the IL-2 gene fragment with restriction enzyme sticky end of embodiment seven gained, and wherein, 1 is pcr amplification product C, and 2 is that pcr amplification product D, M are for marking;
The schema that Figure 15 reacts for the hybridization PCR described in embodiment seven;
Figure 16 is the pIRES2-MART-1-IL-2 recombinant vectors collection of illustrative plates of embodiment eight gained;
Figure 17 is that the enzyme of the pIRES2-MART-1-IL-2 recombinant vectors of embodiment eight gained cuts qualification electrophorogram, wherein, 1 is Xho I/EcoR I double digestion reaction product, and 2 is EcoR I/Not I double digestion reaction product, 3 is Xho I/Not I double digestion reaction product, and M is mark.
Embodiment
In following embodiment, used experimental technique, such as round pcr, design of primers technology, vector construction technology, detection technique, electrophoretic technique etc. are the routine techniques in genetically engineered, those skilled in the art can according to existing techniques in realizing (such as with reference to works such as J. Pehanorm Brookers, " Molecular Cloning: A Laboratory guide " that Huang Peitang etc. translate, Science Press's third edition; Or carry out according to product description).Used in operation equipment, reagent, carrier, bacterial strain etc., be and purchase available conventional products by market.
Embodiment one: obtain the IL-2 gene fragment containing specific cleavage site
1, design of primers
According to the nucleotide sequence (as shown in SEQ ID NO:1 in sequence table) of IL-2 gene and pIRES2-EGFP plasmid vector being expected the multiple clone site inserted, design Auele Specific Primer is as follows:
IL-2 upstream primer (as shown in SEQ ID NO:4 in sequence table):
5 '-CCG
gAATTCaTGTACAGGATGCAACTCC-3 ' (underscore part is EcoR I restriction enzyme site sequence), IL-2 downstream primer (as shown in SEQ ID NO:5 in sequence table):
5 '-CGC
gGATCCtCAAGTCAGTGTTGAGATGATGC-3 ' (underscore part is BamH I restriction enzyme site sequence).
2, cDNA template is obtained
TRIzon method is from CIK cell (Cytokine-Induced Killer, cytokine induced kill cell) or human peripheral be separated mononuclearcell in, extract RNA(TRIzon total RNA extraction reagent box purchased from Beijing CoWin Bioscience Co., Ltd., production code member is CW0580), and reverse transcription becomes cDNA(Reverse Transcription box purchased from precious biotechnology (Dalian) company limited, production code member is RR019A).
3, the IL-2 gene fragment containing specific cleavage site is obtained
With obtained cDNA for template, under the effect of the above-mentioned upstream and downstream primer containing specific cleavage site, IL-2 gene fragment is obtained by PCR reaction, EcoR I restriction enzyme site sequence is contained in its upstream, BamH I restriction enzyme site sequence is contained in downstream, and its nucleotide sequence is as shown in SEQ ID NO:6 in sequence table.Identify with 1% agarose gel electrophoresis, electrophoresis result as shown in Figure 1.
PCR reaction system following (50 μ L):
Wherein, 2 × Prime STAR Max DNA Polymerase is archaeal dna polymerase-damping fluid mixture, and purchased from precious biological (Dalian) company limited, production code member is R045A.
PCR reaction conditions is: 95 DEG C of denaturation 5min; 98 DEG C of sex change 10s, 55 DEG C of annealing 5s, 72 DEG C extend 5s, 30 circulations; 72 DEG C finally extend 5min.
The structure of embodiment two: pIRES2-IL-2-EGFP recombinant vectors
Use restriction enzyme EcoR I and BamH I, enzyme cuts the IL-2 gene fragment of pIRES2-EGFP plasmid (EcoR I, BamH I restriction enzyme site are contained in the multiple clone site place of this plasmid) and embodiment one gained respectively, obtain enzyme cut rear linearizing pIRES2-EGFP carrier and enzyme cut after IL-2 gene order; Adopt T4DNA ligase enzyme system to carry out ligation, hatch 30 minutes at 22 DEG C, then deactivation 5 minutes at 70 DEG C, builds pIRES2-IL-2-EGFP recombinant vectors (as shown in Figure 3).
From the constructional feature (as shown in Figure 2) of pIRES2-EGFP plasmid, after IL-2 gene inserts the multiple clone site of pIRES2-EGFP plasmid, be positioned at the upstream (as shown in Figure 3) of its own sequence IRES of plasmid vector, IL-2 and the EGFP sequence namely under same promotor starts is expressed respectively.
1, double digestion pIRES2-EGFP plasmid
Endonuclease reaction system following (50 μ L):
Wherein, restriction endonuclease EcoR I and 10 × K Buffer is EcoR I restriction endonuclease buffer solution system, and purchased from precious biotechnology (Dalian) company limited, production code member is 1040A; Restriction endonuclease BamH I and 10 × K Buffer is BamH I restriction endonuclease buffer solution system, and purchased from precious biotechnology (Dalian) company limited, production code member is 1094A.
Endonuclease reaction condition: react 6 hours at 37 DEG C.
2, double digestion IL-2 gene fragment
Endonuclease reaction system following (50 μ L):
Endonuclease reaction condition: react 6 hours at 37 DEG C.
3, connect IL-2 gene fragment and pIRES2-EGFP carrier, build pIRES2-IL-2-EGFP recombinant vectors
Ligation system following (20 μ L):
Wherein, T4DNA ligase enzyme and 10 × Ligation Buffer are DNA ligase buffer solution system, and purchased from Beijing CoWin Bioscience Co., Ltd., production code member is CW0805.
Ligation condition: hatch 30 minutes for 22 DEG C, 70 DEG C of deactivations 5 minutes.
4, the qualification of pIRES2-IL-2-EGFP recombinant vectors
In 200 μ L competent cell JM109 (1 ~ 2 × 10
9bacteria/ml), add the above-mentioned ligation product of 20 μ L, after being placed in cooled on ice 30min, being placed in 42 DEG C of water-bath thermal shock 90s, then being placed in cooled on ice 2min, then add LB liquid nutrient medium 780ul; Under 37 DEG C of conditions, on the shaking table of 150 revs/min, 60min is cultivated in recovery, is coated on the LB flat board containing kalamycin resistance by the bacterium liquid of recovering, is inverted cultivation 16 ~ 18 hours at 37 DEG C; Picking positive bacteria drops down onto in kalamycin resistance LB liquid nutrient medium, 37 DEG C, cultivate 12 ~ 16 hours under the condition of 200rpm.
Get positive bacterium colony bacterium liquid, carry out bacterium liquid PCR preliminary evaluation, PCR identification reaction system following (20 μ L):
Wherein, 2 × Power Taq PCR Master Mix is archaeal dna polymerase-enzyme buffer liquid dNTPs mixture, and purchased from hundred Tykes (Beijing) Bioisystech Co., Ltd, production code member is PR1701.
PCR reaction conditions is: 95 DEG C of denaturation 12min; 95 DEG C of sex change 30s, 55 DEG C of annealing 30s, 72 DEG C extend 30s, 30 circulations; 72 DEG C of ends extend 5min.
Get bacterium liquid PCR identification reaction product, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in Figure 4.Electrophoresis result shows, and occurs electrophoretic band at 462bp place, consistent with the molecular size range of goal gene IL-2 gene, shows the success of pIRES2-IL-2-EGFP construction of recombinant vector.
Adopt plasmid extraction kit (purchased from Beijing CoWin Bioscience Co., Ltd., production code member is CW0511), according to the operation of test kit specification sheets, extract the plasmid of positive bacterium colony, carry out enzyme and cut qualification.
Enzyme cuts identification reaction system following (10 μ L):
Endonuclease reaction condition: react 1 hour at 37 DEG C.
Get enzyme and cut identification reaction product, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in Figure 5.Electrophoresis result shows, and occur two band after electrophoresis, wherein one appears at 462bp place, consistent with the molecular size range of goal gene IL-2 gene, shows the success of pIRES2-IL-2-EGFP construction of recombinant vector.
Embodiment three: two PCR method obtains the MART-1 gene fragment with restriction enzyme sticky end
According to MART-1 gene order and pIRES2-EGFP plasmid vector being expected the multiple clone site inserted, design two pairs of length differences, primer with restriction enzyme sticky end; The cDNA of the RNA institute reverse transcription of extracting from melanoma cell A375, as template, carries out pcr amplification with above-mentioned two pairs of primers respectively, obtains two kinds of pcr amplification products; Sex change and annealing is carried out successively by after two kinds of pcr amplification product mixing, obtain four kinds of MART-1 gene fragments, wherein the two ends of two kinds of MART-1 gene fragments are with restriction enzyme sticky end, cutting without the need to using restriction enzyme to carry out enzyme thus, MART-1 gene fragment orientation can be connected in the expection multiple clone site of plasmid vector.
Compared with traditional PCR primer cloning process, present method (two PCR method) has the advantages such as simple, cost is low, efficiency is high, versatility is good, can be widely used in the quick clone of PCR primer.In the method, do not need to use restriction enzyme ferment treatment PCR primer, the DNA fragmentation containing restriction enzyme sticky end can be obtained, the multiple clone site of genophore can be made full use of, without the need to considering whether contain the restriction enzyme site identical with vector multiple cloning site in goal gene, the directed cloning of goal gene easily can be realized.
1, design of primers
According to the nucleotide sequence (as shown in SEQ ID NO:2 in sequence table) of MART-1 gene and pIRES2-EGFP plasmid vector being expected the multiple clone site inserted, design two pairs of length differences, primer with restriction enzyme sticky end, as follows:
MART-1 first primer pair is made up of MART-1 upstream long primer and MART-1 downstream long primer:
MART-1 upstream long primer (as shown in SEQ ID NO:7 in sequence table):
5'-
AACCATGCCAAGAGAAGATGCTCACT-3'
Underscore part is the full sequence in cleavage site downstream in restriction enzyme BstX I recognition sequence, and tilted letter ATG is the initiator codon of MART-1 gene;
MART-1 downstream long primer (as shown in SEQ ID NO:8 in sequence table):
5'-
GGCCGCTTAAGGTGAATAAGGTG-3'
Underscore part is the full sequence in cleavage site downstream in restriction enzyme Not I recognition sequence.
MART-1 second primer pair is made up of MART-1 upstream short primer and MART-1 downstream short primer:
MART-1 upstream short primer (as shown in SEQ ID NO:9 in sequence table):
5'-
ATGCCAAGAGAAGATGCTCACTTCATC-3'
Underscore part is the reverse complementary sequence of the full sequence of cleavage site upstream in restriction enzyme BstX I recognition sequence, and AT is a part for the initiator codon of MART-1 gene;
MART-1 downstream short primer (as shown in SEQ ID NO:10 in sequence table):
5'-
GCTTAAGGTGAATAAGGTGGTGGTGAC-3'
Underscore part is the reverse complementary sequence of the full sequence of cleavage site upstream in restriction enzyme Not I recognition sequence.
MART-1 first primer pair is identical with the target sequence (namely corresponding with MART-1 gene sequence) of MART-1 second primer pair.
The recognition sequence of restriction enzyme BstX I is: 5'-CCANNNNN/NTGG-3'
The recognition sequence of restriction enzyme Not I is: 5'-GC/GGCCGC-3'
2, cDNA template is obtained
TRIzon method extracts RNA(TRIzon total RNA extraction reagent box purchased from Beijing CoWin Bioscience Co., Ltd. from melanoma cell A375, production code member is CW0580), and reverse transcription becomes cDNA(Reverse Transcription box purchased from precious biotechnology (Dalian) company limited, production code member is RR019A).
3, the MART-1 gene fragment with restriction enzyme sticky end is obtained
With the cDNA of the RNA extracted in melanoma cell A375 institute reverse transcription for template, carry out pcr amplification with MART-1 first primer pair, obtain pcr amplification product A; Carry out pcr amplification with MART-1 second primer pair, obtain pcr amplification product B.Pcr amplification product A and pcr amplification product B is all containing MART-1 gene order.
PCR reaction system following (50 μ L):
PCR reaction conditions is: 95 DEG C of denaturation 5min; 98 DEG C of sex change 10s, 55 DEG C of annealing 5s, 72 DEG C extend 5s, 30 circulations; 72 DEG C finally extend 5min.
Get pcr amplification product A and pcr amplification product B respectively, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in Figure 6.Electrophoresis result shows, and the electrophoretic band of pcr amplification product A appears at 367bp place, and the electrophoretic band of pcr amplification product B appears at 359bp place, all consistent with the molecular size range of goal gene.
Get pcr amplification product A respectively and pcr amplification product B checks order, result shows: the 5' end of pcr amplification product A holds many 4 Nucleotide than the 5' of pcr amplification product B, the 3' end of pcr amplification product A also holds many 4 Nucleotide than the 3' of pcr amplification product B, and all the other sequences are identical.
By pcr amplification product A and pcr amplification product B etc. mole of mixing, carry out hybridization PCR and react, obtain MART-1 gene fragment mixture.
Hybridization PCR reaction system following (25 μ L):
Amplified production A(52.5 μM) 10.8 μ L,
Amplified production B(46.1 μM) 12.3 μ L,
Sterile purified water 1.9 μ L.
Hybridization PCR reaction conditions is as follows: 95 DEG C of 5min, 80 DEG C of 1min, 70 DEG C of 1min, 65 DEG C of 1min, 60 DEG C of 1min, 55 DEG C of 1min, 40 DEG C of 1min, 4 DEG C of preservations.
After pcr amplification product A and pcr amplification product B sex change, obtain four kinds of DNA single chains, four kinds of DNA single chain random combines, produce the DNA fragmentation of four kinds of equal proportions---as shown in Figure 7, it is the MART-1 gene order shown in sequence table SEQ ID NO:2 that straight line omits region for MART-1 gene fragment I, MART-1 gene fragment II, MART-1 gene fragment III and MART-1 gene fragment IV().Wherein, MART-1 gene fragment III, MART-1 gene fragment IV are hybridizing DNA fragment.The 5' end of MART-1 gene fragment III has BstX I sticky end, and its 3' end has Not I sticky end.
The structure of embodiment four: pIRES2-IL-2-MART-1 recombinant vectors
Use restriction enzyme BstX I and Not I double digestion pIRES2-IL-2-EGFP recombinant vectors.Because restriction endonuclease BstXI is arranged in the terminal of the IRES sequence downstream of pIRES2-IL-2-EGFP recombinant vectors and the section start of EGFP Sequences upstream, and restriction endonuclease Not I is arranged in the downstream termination point place of the EGFP sequence of pIRES2-IL-2-EGFP recombinant vectors, therefore, after inserting MART-1 gene fragment by these two restriction enzyme sites, MART-1 gene is positioned at the downstream of IRES sequence, thus make IL-2 gene and MART-1 gene lay respectively at the both sides (as shown in Figure 8) of IRES sequence, achieve the coordinate expression of two goal gene, and the generation of fusion rotein can be avoided.
1, Not I endonuclease reaction
Not I endonuclease reaction system following (50 μ L):
Endonuclease reaction condition: react 6 hours at 37 DEG C.
Restriction endonuclease Not I, 10 × H Buffer, BSA(bovine serum albumin) and Triton X-100(Triton X-100) be Not I restriction endonuclease reaction kit, purchased from precious biotechnology (Dalian) company limited, production code member is 1166A.
Adopt DNA fast purifying test kit (purchased from Beijing CoWin Bioscience Co., Ltd., production code member is CW2302) to carry out purifying, collect linearizing pIRES2-IL-2-EGFP recombinant vectors after Not I enzyme is cut.
2, BstX I endonuclease reaction
BstX I endonuclease reaction system following (50 μ L):
Wherein, restriction endonuclease BstX I and 10 × H Buffer is BstX I restriction endonuclease buffer solution system, and purchased from precious biotechnology (Dalian) company limited, production code member is 1027A.
Endonuclease reaction condition: react 6 hours at 37 DEG C.
Adopt DNA fast purifying test kit (purchased from Beijing CoWin Bioscience Co., Ltd., production code member is CW2302) to carry out purifying, collect linearizing pIRES2-IL-2-EGFP recombinant vectors after BstX I enzyme is cut.
3, connect MART-1 gene and pIRES2-IL-2-EGFP recombinant vectors, build pIRES2-IL-2-MART-1 recombinant vectors
MART-1 gene fragment mixture obtained for embodiment three is mixed with pIRES2-IL-2-EGFP recombinant vectors linearizing after double digestion (mol ratio of MART-1 gene fragment and pIRES2-IL-2-EGFP recombinant vectors is 4 ︰ 1), add T4DNA ligase enzyme and carry out ligation, at 22 DEG C, hatch 30 minutes, build pIRES2-IL-2-MART-1 recombinant vectors.
Four kinds of DNA fragmentations in MART-1 gene fragment mixture, MART-1 gene fragment III is only had to have the sticky end with the complementation of pIRES2-IL-2-EGFP recombinant vectors, thus can be connected with pIRES2-IL-2-EGFP recombinant vectors orientation, other three kinds of MART-1 gene fragments all can not be connected with pIRES2-IL-2-EGFP recombinant vectors orientation.
Ligation system following (20 μ L):
Ligation condition: hatch 30 minutes for 22 DEG C, 70 DEG C of deactivations 5 minutes.
4, the qualification of pIRES2-IL-2-MART-1 recombinant vectors
The above-mentioned ligation product of 20 μ L to be joined in 200 μ L competent cell JM109 (1 ~ 2 × 10
9bacteria/ml), after being placed in cooled on ice 30min, being placed in 42 DEG C of water-bath thermal shock 90s, then being placed in cooled on ice 2min; Then add LB liquid nutrient medium 780ul, under 37 DEG C of conditions, on the shaking table of 150 revs/min, 60min is cultivated in recovery, is coated on the LB flat board containing kalamycin resistance by the bacterium liquid of recovering, is inverted cultivation 16 ~ 18 hours at 37 DEG C; Picking positive bacteria drops down onto in kalamycin resistance LB liquid nutrient medium, 37 DEG C, cultivate 12 ~ 16 hours under the condition of 200rpm.
Adopt plasmid extraction kit (purchased from Beijing CoWin Bioscience Co., Ltd., production code member is CW0511), according to the operation of test kit specification sheets, extract the plasmid of positive bacterium colony, carry out enzyme and cut qualification.
Endonuclease reaction system one (10 μ L):
Endonuclease reaction system two (10 μ L):
Endonuclease reaction system three (10 μ L):
Wherein, restriction endonuclease EcoR I and 10 × H Buffer is EcoR I restriction endonuclease buffer solution system, and purchased from precious biotechnology (Dalian) company limited, production code member is 1040A.
Endonuclease reaction condition: react 1 hour at 37 DEG C.
Get above-mentioned endonuclease reaction product respectively, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in Figure 9.Electrophoresis result shows, and occurs two band after EcoR I/BamH I double digestion reaction product electrophoresis, and wherein one at 462bp place, consistent with the molecular size range of goal gene IL-2 gene; Occur two band after BamH I/Not I double digestion reaction product electrophoresis, wherein one at 924bp place, in the same size with the molecular weight sum of goal gene MART-1 gene and IRES sequence; Occur two band after EcoR I/NotI double digestion reaction product electrophoresis, wherein one at 1404bp place, in the same size with the molecular weight sum of goal gene IL-2 gene, MART-1 gene and IRES sequence.Above-mentioned qualification result shows, the success of pIRES2-IL-2-MART-1 plasmid construction.
PIRES2-IL-2-MART-1 recombinant vectors is delivered to gold only intelligence biotechnology (Beijing) company limited check order, consistent with expected results through order-checking, further proof vector construction is successfully.
Embodiment five: obtain the MART-1 gene fragment containing specific cleavage site
According to the nucleotide sequence (as shown in SEQ ID NO:2 in sequence table) of MART-1 gene and pIRES2-EGFP plasmid vector being expected the multiple clone site inserted, design Auele Specific Primer is as follows:
MART-1 upstream primer (as shown in SEQ ID NO:11 in sequence table):
5 '-AA
cTCGAGaTGCCAAGAGAAGATGC-3 ' (underscore part is Xho I restriction enzyme site sequence),
MART-1 downstream primer (as shown in SEQ ID NO:12 in sequence table):
5 '-CG
gAATTCtTAAGGTGAATAAGGTG-3 ' (underscore part is EcoR I restriction enzyme site sequence).
TRIzon method extracts RNA from melanoma cell A375 and reverse transcription becomes cDNA, with this cDNA for template, under the effect of the above-mentioned upstream and downstream primer containing specific cleavage site, MART-1 gene fragment is obtained by PCR reaction (PCR reaction system and reaction conditions reference example one), Xho I restriction enzyme site sequence is contained in its upstream, EcoRI restriction enzyme site sequence is contained in downstream, and its nucleotide sequence is as shown in SEQ ID NO:13 in sequence table.Identify with 1% agarose gel electrophoresis, electrophoresis result as shown in Figure 10.
The structure of embodiment six: pIRES2-MART-1-EGFP recombinant vectors
Use restriction enzyme Xho I and EcoR I, enzyme cuts the MART-1 gene fragment (endonuclease reaction system and reaction conditions reference example two) of pIRES2-EGFP plasmid (Xho I, EcoR I restriction enzyme site are contained in the multiple clone site place of this plasmid) and embodiment five gained respectively, obtain enzyme cut rear linearizing pIRES2-EGFP carrier and enzyme cut after MART-1 gene order; Adopt T4DNA ligase enzyme system to carry out ligation (ligation system and reaction conditions reference example two), hatch 30 minutes at 22 DEG C, 70 DEG C of deactivations 5 minutes, build pIRES2-MART-1-EGFP recombinant vectors (as shown in figure 11).
Get above-mentioned ligation product transfection competent cell JM109, picking positive bacterium colony bacterium liquid, carries out bacterium liquid PCR qualification respectively and enzyme cuts qualification (authentication method reference example two).
Get bacterium liquid PCR identification reaction product, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in figure 12.Electrophoresis result shows, and occurs electrophoretic band at 357bp place, consistent with the molecular size range of goal gene MART-1 gene, shows the success of pIRES2-MART-1-EGFP construction of recombinant vector.
Get enzyme and cut identification reaction product, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in figure 13.Electrophoresis result shows, and occur two band after electrophoresis, wherein one appears at 357bp place, consistent with the molecular size range of goal gene MART-1 gene, shows the success of pIRES2-MART-1-EGFP construction of recombinant vector.
Embodiment seven: two PCR method obtains the IL-2 gene fragment with restriction enzyme sticky end
According to IL-2 gene order and pIRES2-EGFP plasmid vector being expected the multiple clone site inserted, design two pairs of length differences, primer with restriction enzyme sticky end; With the cDNA of the RNA extracted in CIK cell institute reverse transcription for template, carry out pcr amplification with above-mentioned two pairs of primers respectively, obtain two kinds of pcr amplification products; Sex change and annealing is carried out successively by after two kinds of pcr amplification product mixing, obtain four kinds of IL-2 gene fragments, wherein the two ends of two kinds of IL-2 gene fragments are with restriction enzyme sticky end, cutting without the need to using restriction enzyme to carry out enzyme thus, IL-2 gene fragment orientation can be connected in the expection multiple clone site of plasmid vector.
1, design of primers
According to the nucleotide sequence (as shown in SEQ ID NO:1 in sequence table) of IL-2 gene and pIRES2-EGFP plasmid vector being expected the multiple clone site inserted, design two pairs of length differences, primer with restriction enzyme sticky end, as follows:
IL-2 first primer pair is made up of IL-2 upstream long primer and IL-2 downstream long primer:
IL-2 upstream long primer (as shown in SEQ ID NO:14 in sequence table):
5'-
AACCATGTACAGGATGCAACTCCTGTCTT-3'
Underscore part is the full sequence in cleavage site downstream in restriction enzyme BstX I recognition sequence, and tilted letter ATG is the initiator codon of IL-2 gene;
IL-2 downstream long primer (as shown in SEQ ID NO:15 in sequence table):
5'-
GGCCGCTCAAGTCAGTGTTGAGATGAT-3'
Underscore part is the full sequence in cleavage site downstream in restriction enzyme Not I recognition sequence.
IL-2 second primer pair is made up of IL-2 upstream short primer and IL-2 downstream short primer:
IL-2 upstream short primer (as shown in SEQ ID NO:16 in sequence table):
5'-
ATGTACAGGATGCAACTCCTGTCTT-3'
Underscore part is the reverse complementary sequence of the full sequence of cleavage site upstream in restriction enzyme BstX I recognition sequence, and AT is a part for the initiator codon of IL-2 gene;
IL-2 downstream short primer (as shown in SEQ ID NO:17 in sequence table):
5'-
GCTCAAGTCAGTGTTGAGATGATGC-3'
Underscore part is the reverse complementary sequence of the full sequence of cleavage site upstream in restriction enzyme Not I recognition sequence.
IL-2 first primer pair is identical with the target sequence (namely corresponding with IL-2 gene sequence) of IL-2 second primer pair.
2, the IL-2 gene fragment with restriction enzyme sticky end is obtained
TRIzon method, from the mononuclearcell that CIK cell or human peripheral are separated, extracts RNA and reverse transcription becomes cDNA.With obtained cDNA for template, carry out pcr amplification with IL-2 first primer pair, obtain pcr amplification product C; Carry out pcr amplification with IL-2 second primer pair, obtain pcr amplification product D.Pcr amplification product C and pcr amplification product D is all containing IL-2 gene order.PCR reaction system and reaction conditions reference example three.
Get pcr amplification product C and pcr amplification product D respectively, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in figure 14.Electrophoresis result shows, and the electrophoretic band of pcr amplification product C appears at 472bp place, and the electrophoretic band of pcr amplification product D appears at 464bp place, all consistent with the molecular size range of goal gene.
By pcr amplification product C and pcr amplification product D etc. mole of mixing, carry out hybridization PCR and react, obtain IL-2 gene fragment mixture.The reaction system of hybridization PCR reaction and reaction conditions reference example three.
After pcr amplification product C and pcr amplification product D sex change, obtain four kinds of DNA single chains, four kinds of DNA single chain random combines, produce the DNA fragmentation of four kinds of equal proportions---as shown in figure 15, it is the IL-2 gene order shown in sequence table SEQ ID NO:1 that straight line omits region for IL-2 gene fragment V, IL-2 gene fragment VI, IL-2 gene fragment VII and IL-2 gene fragment VIII().Wherein, IL-2 gene fragment VII, IL-2 gene fragment VIII are hybridizing DNA fragment.The 5' end of IL-2 gene fragment VII has BstX I sticky end, and its 3' end has Not I sticky end.
The structure of embodiment eight: pIRES2-MART-1-IL-2 recombinant vectors
Use restriction enzyme BstX I and Not I double digestion pIRES2-MART-1-EGFP recombinant vectors, endonuclease reaction system and reaction conditions reference example four.Adopt DNA fast purifying test kit to carry out purifying, collect linearizing pIRES2-MART-1-EGFP recombinant vectors after double digestion.
IL-2 gene fragment mixture obtained for embodiment seven is mixed with pIRES2-MART-1-EGFP recombinant vectors linearizing after double digestion (mol ratio of IL-2 gene fragment and pIRES2-MART-1-EGFP recombinant vectors is 4 ︰ 1), add T4DNA ligase enzyme and carry out ligation (ligation system reference example four), 30 minutes are hatched at 22 DEG C, deactivation 5 minutes at 70 DEG C, constructs pIRES2-MART-1-IL-2 recombinant vectors (as shown in figure 16).
Four kinds of DNA fragmentations in IL-2 gene fragment mixture, IL-2 gene fragment VII is only had to have the sticky end with the complementation of pIRES2-MART-1-EGFP recombinant vectors, thus can be connected with pIRES2-MART-1-EGFP recombinant vectors orientation, other three kinds of IL-2 gene fragments all can not be connected with pIRES2-MART-1-EGFP recombinant vectors orientation.
Get above-mentioned ligation product transfection competent cell JM109, the plasmid of the positive bacterium colony of picking, carries out enzyme and cuts qualification.
Endonuclease reaction system one (10 μ L):
Wherein, restriction endonuclease Xho I, 10 × H Buffer are Xho I restriction endonuclease reaction kit, and purchased from precious biotechnology (Dalian) company limited, production code member is 1094A.
Endonuclease reaction system two (10 μ L):
Endonuclease reaction system three (10 μ L):
Endonuclease reaction condition: react 1 hour at 37 DEG C.
Get above-mentioned endonuclease reaction product respectively, identify with 1% agarose gel electrophoresis, electrophoresis result as shown in figure 17.Electrophoresis result shows, and occurs two band after Xho I/EcoR I double digestion reaction product electrophoresis, and wherein one at 357bp place, consistent with the molecular size range of goal gene MART-1 gene; Occur two band after EcoR I/Not I double digestion reaction product electrophoresis, wherein one at 1047bp place, in the same size with the molecular weight sum of goal gene IL-2 gene and IRES sequence; Occur two band after XhoI/Not I double digestion reaction product electrophoresis, wherein one at 1404bp place, in the same size with the molecular weight sum of goal gene MART-1 gene, IL-2 gene and IRES sequence.Qualification result shows, the success of pIRES2-MART-1-IL-2 construction of recombinant vector.
PIRES2-MART-1-IL-2 recombinant vectors is delivered to gold only intelligence biotechnology (Beijing) company limited check order, consistent with expected results through order-checking, further proof vector construction is successfully.
The above embodiment only have expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but therefore can not be interpreted as the restriction to the scope of the claims of the present invention.It should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (2)
- The preparation method of 1.IL-2 and MART-1 double gene coexpression recombinant vectors pIRES2-IL-2-MART-1, comprises the following steps:A) the IL-2 gene fragment containing specific cleavage site is obtained: obtain cDNA as template from CIK cell, pcr amplification is carried out with the IL-2 Auele Specific Primer containing EcoR I and BamH I restriction enzyme site sequence, obtain the IL-2 gene fragment containing EcoR I and BamHI restriction enzyme site, its nucleotide sequence is as shown in SEQ ID NO:6 in sequence table;B) build pIRES2-IL-2-EGFP recombinant vectors: with restriction enzyme EcoR I, BamH I respectively enzyme cut pIRES2-EGFP plasmid and steps A) the IL-2 gene fragment that obtains, and adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-IL-2-EGFP recombinant vectors;C) the MART-1 gene fragment of cutting sticky end containing enzyme is obtained: obtain cDNA as template from melanoma cell A375, pcr amplification is carried out with the MART-1 Auele Specific Primer cutting sticky end containing BstX I and Not I enzyme, the PCR reaction product obtained is carried out hybridization PCR again and is reacted, obtain MART-1 gene fragment mixture, a kind of MART-1 gene fragment wherein has BstX I and Not I enzyme cuts sticky end;D) pIRES2-IL-2-MART-1 recombinant vectors is built: cut step B with restriction enzyme BstX I, Not I enzyme) the pIRES2-IL-2-EGFP recombinant vectors that obtains, by step C) the MART-1 gene fragment mixture and the enzyme that obtain cut rear linearizing pIRES2-IL-2-EGFP recombinant vectors and mix, adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-IL-2-MART-1 recombinant vectors;Wherein, steps A) described in IL-2 Auele Specific Primer be:IL-2 upstream primer: 5 '-CCGGAATTCATGTACAGGATGCAACTCC-3 ',IL-2 downstream primer: 5 '-CGCGGATCCTCAAGTCAGTGTTGAGATGATGC-3 ';Steps A) reaction conditions of described pcr amplification is: 95 DEG C of denaturation 5min; 98 DEG C of sex change 10s, 55 DEG C of annealing 5s, 72 DEG C extend 5s, 30 circulations; 72 DEG C finally extend 5min;Step C) described in MART-1 Auele Specific Primer comprise MART-1 first primer pair and MART-1 second primer pair, described MART-1 first primer pair is made up of MART-1 upstream long primer and MART-1 downstream long primer, and described MART-1 second primer pair is made up of MART-1 upstream short primer and MART-1 downstream short primer:MART-1 first primer pair is:MART-1 upstream long primer: 5'-AACCATGCCAAGAGAAGATGCTCACT-3',MART-1 downstream long primer: 5'-GGCCGCTTAAGGTGAATAAGGTG-3';MART-1 second primer pair is:MART-1 upstream short primer: 5'-ATGCCAAGAGAAGATGCTCACTTCATC-3',MART-1 downstream short primer: 5'-GCTTAAGGTGAATAAGGTGGTGGTGAC-3';Step C) reaction conditions of described pcr amplification is: 95 DEG C of denaturation 5min; 98 DEG C of sex change 10s, 55 DEG C of annealing 5s, 72 DEG C extend 5s, 30 circulations; 72 DEG C finally extend 5min;Step C) reaction conditions that reacts of described hybridization PCR is: 95 DEG C of 5min, 80 DEG C of 1min, 70 DEG C of 1min, 65 DEG C of 1min, 60 DEG C of 1min, 55 DEG C of 1min, 40 DEG C of 1min, 4 DEG C of preservations.
- The preparation method of 2.IL-2 and MART-1 double gene coexpression recombinant vectors pIRES2-MART-1-IL-2, comprises the following steps:A) the MART-1 gene fragment containing specific cleavage site is obtained: obtain cDNA as template from melanoma cell A375, pcr amplification is carried out with the MART-1 Auele Specific Primer containing Xho I and EcoR I restriction enzyme site sequence, obtain the MART-1 gene fragment containing Xho I and EcoR I restriction enzyme site, its nucleotide sequence is as shown in SEQ ID NO:13 in sequence table;B) build pIRES2-MART-1-EGFP recombinant vectors: with restriction enzyme Xho I, EcoR II respectively enzyme cut the MART-1 gene fragment that pIRES2-EGFP plasmid and step a) obtain, and adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-MART-1-EGFP recombinant vectors;C) the IL-2 gene fragment of cutting sticky end containing enzyme is obtained: obtain cDNA as template from CIK cell, pcr amplification is carried out with the IL-2 Auele Specific Primer cutting sticky end containing BstX I and Not I enzyme, the PCR reaction product obtained is carried out hybridization PCR again and is reacted, obtain IL-2 gene fragment mixture, a kind of IL-2 gene fragment wherein has BstX I and Not I enzyme cuts sticky end;D) pIRES2-MART-1-IL-2 recombinant vectors is built: cut step b with restriction enzyme BstX I, Not I enzyme) the pIRES2-MART-1-EGFP recombinant vectors that obtains, by step c) the IL-2 gene fragment mixture and the enzyme that obtain cut rear linearizing pIRES2-MART-1-EGFP recombinant vectors and mix, adopt T4DNA ligase enzyme to carry out ligation, obtain pIRES2-MART-1-IL-2 recombinant vectors;Wherein, step a) described in MART-1 Auele Specific Primer be:MART-1 upstream primer: 5 '-AACTCGAGATGCCAAGAGAAGATGC-3 ',MART-1 downstream primer: 5 '-CGGAATTCTTAAGGTGAATAAGGTG-3 ';The reaction conditions of step a) described pcr amplification is: 95 DEG C of denaturation 5min; 98 DEG C of sex change 10s, 55 DEG C of annealing 5s, 72 DEG C extend 5s, 30 circulations; 72 DEG C finally extend 5min;Step c) described in IL-2 Auele Specific Primer comprise IL-2 first primer pair and IL-2 second primer pair, described IL-2 first primer pair is made up of IL-2 upstream long primer and IL-2 downstream long primer, and described IL-2 second primer pair is made up of IL-2 upstream short primer and IL-2 downstream short primer:IL-2 first primer pair is:IL-2 upstream long primer: 5'-AACCATGTACAGGATGCAACTCCTGTCTT-3',IL-2 downstream long primer: 5'-GGCCGCTCAAGTCAGTGTTGAGATGAT-3';IL-2 second primer pair is:IL-2 upstream short primer: 5'-ATGTACAGGATGCAACTCCTGTCTT-3',IL-2 downstream short primer: 5'-GCTCAAGTCAGTGTTGAGATGATGC-3';Step c) reaction conditions of described pcr amplification is: 95 DEG C of denaturation 5min; 98 DEG C of sex change 10s, 55 DEG C of annealing 5s, 72 DEG C extend 5s, 30 circulations; 72 DEG C finally extend 5min;Step c) reaction conditions that reacts of described hybridization PCR is: 95 DEG C of 5min, 80 DEG C of 1min, 70 DEG C of 1min, 65 DEG C of 1min, 60 DEG C of 1min, 55 DEG C of 1min, 40 DEG C of 1min, 4 DEG C of preservations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310571900.7A CN103555763B (en) | 2013-11-15 | 2013-11-15 | IL-2 and MART-1 double gene coexpression recombinant vectors and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310571900.7A CN103555763B (en) | 2013-11-15 | 2013-11-15 | IL-2 and MART-1 double gene coexpression recombinant vectors and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103555763A CN103555763A (en) | 2014-02-05 |
| CN103555763B true CN103555763B (en) | 2015-11-04 |
Family
ID=50010109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310571900.7A Active CN103555763B (en) | 2013-11-15 | 2013-11-15 | IL-2 and MART-1 double gene coexpression recombinant vectors and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103555763B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106929529A (en) * | 2017-04-22 | 2017-07-07 | 中山大学附属第医院 | Eukaryotic expression system of IL 2 and IFN γ albumen coexpression and its preparation method and application |
| CN110760535A (en) * | 2019-10-23 | 2020-02-07 | 青岛宁逸生物科技有限公司 | Vector for in vitro transcription of mRNA (messenger ribonucleic acid), construction method thereof, method for obtaining mRNA by using vector transcription and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102181430A (en) * | 2011-02-28 | 2011-09-14 | 新乡医学院 | Method for preparing target deoxyribonucleic acid (DNA) fragment with cohesive terminuses of restriction enzyme at both ends |
-
2013
- 2013-11-15 CN CN201310571900.7A patent/CN103555763B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102181430A (en) * | 2011-02-28 | 2011-09-14 | 新乡医学院 | Method for preparing target deoxyribonucleic acid (DNA) fragment with cohesive terminuses of restriction enzyme at both ends |
Non-Patent Citations (8)
| Title |
|---|
| CEA/B7-1、CEA/IL-2核酸疫苗特异性抗结直肠癌免疫的实验研究;何天霖;《中国博士学位论文全文数据库》;20030315(第01期);全文 * |
| IL-2与HSV-1糖蛋白D共表达核酸疫苗的免疫效果研究;李伟荣等;《中国临床神经科学》;20061231;第14卷(第2期);154-158 * |
| MAGE-1与IL-18共表达DNA疫苗的构建及体内外功能验证;时阳;《中国博士学位论文全文数据库》;20041215(第04期);全文 * |
| Twin PCRs: a simple and efficient method for directional cloning of PCR products;Xie Bohong，et al.;《World J Microbiol Biotechnol》;20110130;第27卷(第9期);2223-2225 * |
| 内部核糖体进入位点控制人癌胚抗原与IL-2的共表达;何天霖等;《中国普通外科杂志》;20021130;第11卷(第11期);668-670 * |
| 癌胚抗原DNA疫苗对特异性抗肿瘤免疫的激活及其效应的增强策略;王中川;《中国博士学位论文全文数据库》;20051015(第06期);摘要，第39、58、91页 * |
| 肿瘤相关抗原MART-1蛋白原核表达载体的构建、表达纯化和活性鉴定;孟昭婷等;《解放军医学杂志》;20110901;第36卷(第9期);909-911 * |
| 重组共表达载体pSLC-IRES-IL-2的构建及在COS-7细胞中的表达;侯丽等;《细胞与分子免疫学杂志》;20051231;第21卷(第5期);561-564 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103555763A (en) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103555762B (en) | AFP and GM-CSF dual-gene co-expression recombinant vector as well as preparation method and application of recombinant vector | |
| WO2019080538A1 (en) | Chimeric antigen receptor, nk cell modified by same, coding dna, mrna, expression vector, preparation method and application | |
| US11648306B2 (en) | Non-integrative listeria-based vaccine and method for inducing antitumor immune response | |
| CN107574138A (en) | One plant of Escherichia coli antineoplastic target engineered strain and its construction method and application | |
| CN103614414A (en) | AFP (Alpha Fetoprotein) and IL-2 (Interleukin-2) double-gene co-expressing recombinant vector as well as preparation method and application thereof | |
| Zhang et al. | Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer | |
| CN108840947A (en) | Bovine albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of ox long-acting interferon | |
| CN116396974B (en) | African swine fever virus antigen protein recombinant expression vector, recombinant plant lactobacillus, and preparation method and application thereof | |
| CN103555763B (en) | IL-2 and MART-1 double gene coexpression recombinant vectors and its preparation method and application | |
| CN103550789B (en) | Preparation and application of oral tumor vaccine with attenuated salmonella typhimurium as vector | |
| CN103739682A (en) | Protein with immunogenicity on cervical cancer and application thereof | |
| AU2003206664A1 (en) | Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors | |
| CN112538452A (en) | Cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and preparation method thereof | |
| CN107286255A (en) | It is a kind of by OVA, chicken interferon gamma and chicken interferon α fusion protein constituted and preparation method thereof | |
| CN103602695B (en) | GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) and MART-1 (Melanoma Antigen Recognized By T-Cells 1) dual-gene co-expression recombinant vector and preparation method and application thereof | |
| CN103602706B (en) | MUC1 (Mucins 1) and GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) dual-gene co-expression recombinant vector and preparation method and application thereof | |
| CN103555764B (en) | MUC1 (Mucins) and IL-2 double-gene coexpression recombinant vector as well as preparation method and application thereof | |
| CN107217066A (en) | The method and its application of DNA fragmentation and the recombinant vector containing the fragment, structure recombinant vector | |
| Ahsan et al. | Comparative analysis of macrophage associated vectors for use in genetic vaccine | |
| CN102839186A (en) | Preparation and application of recombinant Mycobacterium smegmatis expressing NY-ESO-1 | |
| CN113832115A (en) | Fusion gene RIL-7 combined CCL19 recombinant oncolytic vaccinia virus and application thereof in preparation of antitumor drugs | |
| CN108840934B (en) | Recombinant sheep long-acting interferon tau, fusion protein for preparing long-acting interferon tau and preparation method of fusion protein | |
| CN104721835A (en) | Melanoma inhibiting DNA plasmid vaccine and preparation method thereof | |
| CN105251001A (en) | High efficiency molecular adjuvant of new castle disease DNA vaccine as well as preparation method and application thereof | |
| CN103421800B (en) | Recombinant gene, recombinant carrier and recombinant cell for treating spinal cord injuries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |